

ה- 2 ביולי, 2014

לכבוד
פרופ' דרור מבורך
המועצה המדעית של הר"י
יו"ר ועדת הבחינות העליונה

הנדון: ספרות מחייבת לבחינת סיום התמחות באנדוקרינולוגיה לשנת 2014

פרופ' מבורך הנכבד,

להלן חומר הלימוד עליו תתבסס בחינת סוף ההתמחות באנדוקרינולוגיה:

- (1) ספר לימוד: עדיפות ניתנת ל- Williams Textbook of Endocrinology, מהדורה 12, 2011.
- (2) מאמרי Review , Update ו- "Approach to the patient" אשר הופיעו ב- Journal of Clinical Endocrinology and Metabolism בשנים 2012-2014.
- (3) Clinical Guidelines של ה- American Endocrine Society (מפורסמים ב-JCEM ובאתר של American Endocrine Society).
- (4) Standards of Medical Care in Diabetes-2014, שהתפרסם ב- Diabetes care 37 Supplement 1 S14-S80
- (5) הנחיות קליניות של האגודה האמריקאית לתירואדולוגיה בנושא הטיפול בסרטן ממין של בלוטת התריס *
Cooper Ds et al. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2009 Nov;19(11):1167-214.
*אנא שימו לב כי אמורה להתפרסם מהדורה חדשה של קווים מנחים אלה, הנבחנו מתבקשים לעקוב ולראות אם אלה יפורסמו טרם הבחינה, אלה הקווים שיקבעו.

מאמרים וסקירות בנושאים אנדוקריניים שהופיעו ב- New Engl J of Med בשנים 2014-2012. ומאמרים פורצי דרך בנושאים אנדוקריניים שהופיעו בכתבי העת הקליניים המובילים (Lancet, JAMA, Arch Intern Med, Annals Intern Med, BMJ).

בשל היותו ספר הלימוד בן כ-3 שנים, מובאת להלן רשימת מאמרים נוספים אשר נדרשת קריאתם. חלקם כבר כלולים בקטגוריה של "עדכון, סקירות, גישה לחולה עם..." שהובאה לעיל, וחלקם מאמרים פורצי דרך בעיתונות הרפואית הכללית של 5-6 השנים האחרונות, אך החובה לקרוא אותם מודגשת ע"י הרשימה הבאה.

Diabetes and Metabolism (obesity, hypoglycemia, lipids)

1. Vasilakou D, Tsapas A. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262.
2. Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2(5)
3. Umpierrez GE et al. Management of Hyperglycemia in Hospitalized Patient in Non-Critical Care Setting: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, January 2012, 97 (1):16–38.
4. McKulloch DK et al. UpToDate :Management of diabetes mellitus in hospitalized patients .<http://www.uptodate.com/contents/management-of-diabetes-mellitus-in-hospitalized-patients>
5. Rosenstock J et al Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. Diabetes Care. 2012 May;35(5):955-8.

6. Buse J et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. *Ann Intern Med* 2011 Jan 18;154(2):103-12
7. Scirica BM., et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus (SAVOR-TIMI). *N Engl J Med* 2013; 369:1317-1326
8. White WB et al. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes *N Engl J Med* 2013; 369:1327-1335
9. The Look Ahead research group. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. *N Engl J Med* 2013;369:145-54
10. Blumer I et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab.* 2013 Nov;98(11):4227-49
11. Inzucchi SE et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia.* 2012 Jun; 55(6):1577-96
12. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus *Diabetes Care* January 2014, vol. 37 no. Supplement 1 S81-S90
13. Berglund L et al. Endocrine society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2012 Sep;97(9):2969-89
14. Khera AV., Plutzki J. Management of low levels of high density cholesterol. A Clinician Update. *Circulation.* 2013, 128:72-78

15. Pha-Hug et al. Genetic testing in patients with obesity. Best Practice & Research Clinical Endocrinology & Metabolism 26 (2012) 133–143
16. Schauer PR et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 3-Year Outcomes. New Engl. J Med 2014; 370:2002-2013
17. Kitabchi AE et al. Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults. UpToDate.
<http://www.uptodate.com/contents/treatment-of-diabetic-ketoacidosis-and-hyperosmolar-hyperglycemic-state-in-adults>
18. Mc Kulloch DK et al. Classification of diabetes mellitus and genetic diabetic syndromes. UpToDate.
<http://www.uptodate.com/contents/classification-of-diabetes-mellitus-and-genetic-diabetic-syndromes>
19. Mc Kulloch DK et al. Estimation of blood glucose control in diabetes mellitus. UpToDate. <http://www.uptodate.com/contents/estimation-of-blood-glucose-control-in-diabetes-mellitus>
20. Bodnar TW et al. Management of Non-Islet-Cell Tumor Hypoglycemia: A Clinical Review. J Clin Endocrinol Metab 99: 713–722, 2014
21. Cryer PE et al. Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. JCEM, 2009, 94(3):709-728
22. Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med. 2008 Jun 12; 358(24):2545-59

23. Patel A, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ADVANCE Collaborative Group. N Engl J Med. 2008 Jun 12; 358(24):2560-72.
24. Ginsberg HN, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. Accord lipids. ACCORD Study Group. N Engl J Med. 2010 Apr 29;362(17):1563-74.
25. AIM HIGH investigators. Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. N Engl J Med 2011; 365:2255-2267
26. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013 May;34(17):1279-91

Thyroid

1. De Groot L et al. Management of thyroid dysfunction during pregnancy and the postpartum: an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 2012 97: 2543–2511
2. Bahn RS et al. The American Thyroid Association and American Association of Clinical Endocrinologists Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis, Thyroid. June 2011, 21(6): 593-646

3. Bonnema SJ, Hegedus L. Radioiodine Therapy in Benign Thyroid Diseases: Effects, Side Effects, and Factors Affecting Therapeutic Outcome. 33 (6) , pp. 920–980, 2012.
4. Garber JR et al. ATA/AACE Guidelines for Hypothyroidism in Adults, Endocr Pract. 2012;18(No. 6)
5. Cooper DS et al. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer, THYROID Volume 19, Number 11: 1167-1214, 2009
6. Ali SZ, Cibas ES, eds. The Bethesda System for reporting thyroid cytopathology. Am J Clin Pathol 2009;132:658-665
7. Nikiforov YE, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011;96:3390-7
8. Horvath E et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab. 2009 May;94(5):1748-51.
9. Choueiri TK et al. Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects. UpToDate.
<http://www.uptodate.com/contents/toxicity-of-molecularly-targeted-antiangiogenic-agents-non-cardiovascular-effects>
10. Wells SA, Santoro M. Update: the status of clinical trials with kinase inhibitors in thyroid cancer. J Clin Endocrinol Metab. 2014 May;99(5):1543-55.

Bone

1. Glenneding P. Markers of Bone Turnover for the Prediction of Fracture Risk and Monitoring of Osteoporosis Treatment: A Need for International Reference. Standards. Osteoporos Int (2011) 22:391–420
2. European Medicines Agency recommends that Protelos/Osseor remain available but with further restrictions. February 2014,
http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Protelos_and_Osseor/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500161968.pdf
3. 3. 2014 IOF Clinician's guide to prevention and treatment of osteoporosis
Downloadable at
<http://nof.org/files/nof/public/content/file/2610/upload/895.pdf>
4. McClung MR et al. Romosozumab in Postmenopausal Women with Low Bone Mineral Density. N Engl J Med 2014;370:412-20.

Pituitary

1. Freda PU et al. Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96: 894–904, 2011
2. Swearingen B et al. Transsphenoidal surgery for pituitary adenomas and other sellar masses. UpToDate.
<http://www.uptodate.com/contents/transsphenoidal-surgery-for-pituitary-adenomas-and-other-sellar-masses>

3. Fenske W, Allolio B. Differential Diagnosis of Diabetes Insipidus J Clin Endocrinol Metab, October 2012, 97(10):3426–3437

Adrenal, sexual differentiation, reproduction

1. Hembree WC et al. Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline J Clin Endocrinol Metab, September 2009, 94(9):3132–3154
2. LeGro RS et al. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. December 2013, JCEM jc.2013–2350.
3. Merke DP. Approach to the adult with adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2008 93: 653
4. Panay N, Lau EO. Management of premature ovarian failure. Best practice & research clinical obstetrics and gynecology. Volume 23, Issue 1, February 2009, Pages 129-140
5. Kannan et al. Evaluation of patients with adrenal incidentalomas, Current opinion in Current Opinion in Endocrinology, Diabetes & Obesity, June 2013 Volume 20 - Issue 3 - p 161–169
6. Snyder PJ. Clinical features and diagnosis of male hypogonadism. UpToDate. <http://www.uptodate.com/contents/clinical-features-and-diagnosis-of-male-hypogonadism>

7. Nieman LK et al. Pathogenesis of autoimmune adrenal insufficiency.
<http://www.uptodate.com/contents/pathogenesis-of-autoimmune-adrenal-insufficiency>
8. Fassnacht M et al. Update in Adrenocortical Carcinoma. J Clin Endocrinol Metab. 98: 4551-4564, 2013
9. Speiser PW et al. Congenital Adrenal Hyperplasia Due to Steroid 21-hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. September 2010, Vol. 95(9):4133–4160.
10. Beuschlein F et al. Constitutive Activation of PKA Catalytic Subunit in Adrenal Cushing's Syndrome. N Engl J Med 2014; 370:1019-1028
11. Bertagna X, Guignat L. Approach to the Cushing's disease patient with persistent/recurrent hypercortisolism after pituitary surgery. J Clin Endocrinol Metab. 2013 Apr;98(4):1307-18
12. Silveira LF, Latronico AC. Approach to Hypogonadotropic Hypogonadism. J Clin Endocrinol Metab, May 2013, 98(5):1781–1788
13. Handelsman DJ, Wartofsky L. Requirement for Mass Spectrometry Sex Steroid Assays in the Journal of Clinical Endocrinology and Metabolism. J Clin Endocrinol Metab, October 2013, 98(10):3971–3973

Neuroendocrine tumors, polyendocrine syndromes

1. Jensen TJ et al. ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive

System: Well-Differentiated Pancreatic Non Functioning Tumors.

Neuroendocrinology 2012;95:120–134

2. Rosenberg PM et al. Glucagonoma and the glucagonoma syndrome.

UpToDate. <http://www.uptodate.com/contents/glucagonoma-and-the-glucagonoma-syndrome>

בברכה,

ד"ר יונתן ארבל

ד"ר קרן תורגמן

יו"ר ועדת הבחינה באנדוקרינולוגיה